Bojan Macanovic

Bojan Macanovic

Auto-generated profile, based on publicly available information

Bojan Macanovic

CUH/UCC Cancer Centre , Wilton , Cork, T12 EC8P

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2023 in Digital Health
Verified
Journal Article
Open access
BMBojan Macanovic
Bojan Macanovic
DODavid O’rEilly
David O’rEilly
HHHarry Harvey
Harry Harvey
DHDanial Hadi
Danial Hadi
MCMaeve Cloherty
Maeve Cloherty
SOSeamus O'Reilly
Seamus O'Reilly
Purpose: To investigate the feasibility of implementing a remote patient monitoring system using an electronic patient-reported outcomes (ePROs) platform in a tertiary cancer center in the Republic of Ireland. Methods: Patients receiving oral chemotherapy and oncology clinicians were invited to participate in the study. Patients were asked to submit weekly symptom questionnaires through an ePRO mobile phone application (app)—ONCOpatient®. Clinical staff were invited to use the ONCOpatient® clinician interface. After 8 weeks all participants submitted evaluation questionnaires. Results: Thirteen patients and five staff were enrolled in the study. The majority of patients were female (85%) with a median age of 48 years (range 22–73). Most (92%) were enrolled over telephone requiring on average 16 minutes. Compliance with the weekly assessments was 91%. Alerts were triggered by 40% of patients who then required phone calls to aid with symptom management. At the end of study, 87% of patients reported they would use the app frequently, 75% reported that the platform met their expectations, and 25% that it exceeded their expectations. Similarly, 100% of staff reported they would use the app frequently, 60% reported that it met their expectations, and 40% that it exceeded their expectations. Conclusions: Our pilot study showed that it is feasible to implement ePRO platforms in the Irish clinical setting. Small sample bias was recognized as a limitation, and we plan to confirm our findings on a larger cohort of patients. In the next phase we will integrate wearables including remote blood pressure monitoring.

21 June 2024 in The Oncologist
Verified
Journal Article
Open access
PDF file
DODavid O’rEilly
David O’rEilly
AFAbdul Rehman Farooq
Abdul Rehman Farooq
PSPaul Nevins Selvadurai
Paul Nevins Selvadurai
LSLaura Sheehan
Laura Sheehan
KMKaren Molan
Karen Molan
CKCatherine Kelly
Catherine Kelly
Early discontinuation of endocrine therapy (ET) is higher among patients with early breast cancer (EBC) compared to patients with metastatic hormone receptor-positive (HR+) breast cancer (MBC). In our clinical experience the reasons for this may include a significant burden of ET side effects impacting quality of life (QOL) in patients with EBC. We hypothesized that QOL is lower in patients with HR + EBC compared to patients with HR + MBC on ET. We conducted a cross-sectional observational study to assess QOL utilizing FACT-ES & EORTC QLQ C30 tools among patients with EBC and MBC receiving ET across 5 Irish hospitals. A total of 417 patients were enrolled—EBC (79% n = 331) and MBC 21% (n = 86). Using the FACT-ES, we found no difference in overall QOL by stage (139.2 vs 141, P = .33). Patients with HR + MBC had a lower symptom burden from ET compared to HR + EBC (61.4 vs 54, P < .01). In adjusted multivariate linear regression models, there was no difference in QOL for patients with EBC and MBC receiving ET. There was no significant difference in overall QOL for patients with EBC and MBC. However, patients with EBC experienced more endocrine symptoms. In adjusted multivariate linear regression models, the stage did not predict QOL. Our results suggest that endocrine symptoms are significant contributors to impaired QOL for patients with EBC but the role of other determinants of QOL (eg, stage) is less clear. Future work could include the development of stage-specific QOL tools and utilization of electronic patient-reported outcomes (ePROs) to identify and manage emergent toxicities.

20 October 2023 in Annals of Oncology
Verified
Journal Article
Closed access
RKR. Kieran
R. Kieran
KCKathryn E Coakley
Kathryn E Coakley
TCT. Cronin
T. Cronin
CWCatherine Sarah Weadick
Catherine Sarah Weadick
BMB. Macanovic
B. Macanovic
SOS. O'Reilly
S. O'Reilly